Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA254
  • Published: 
Download guidance (PDF)

6 Recommendations for further research

6.1

The Committee recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

6.2

The Committee recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.